Does Rapamycin Halt HCM in Cats?
Hypertrophic cardiomyopathy (HCM) affects up to 15-20% of cats, progressing silently until sudden heart failure strikes. Rapamycin, through targeted mTOR inhibition, shows measurable reductions in heart wall thickness, as proven in clinical trials like RAPACAT. Hero Veterinary provides access to these innovative treatments, helping cat owners extend their pets' quality lives with early intervention protocols. What Is the Current State of HCM in Cats? Hypertrophic cardiomyopathy remains the leading heart disease in cats, impacting 15% of the general population and over 30% in breeds like Maine Coon and Ragdoll. A 2023 veterinary report estimates that 1 in 7 asymptomatic cats carries subclinical HCM, detected only via echocardiography. Without intervention, 20-30% progress to clinical stages within 2-3 years, leading to heart failure or thromboembolism. Owners face delayed diagnoses, as early HCM lacks obvious signs like lethargy or coughing. Routine screenings reveal elevated NT-pr...